Bausch Health Hit as Xifaxan Successor Flunks Trials

Why It Matters

The trial failures jeopardize a projected multi‑billion‑dollar revenue stream and intensify pressure on Bausch Health to replace earnings from its aging flagship drug, impacting investors and the broader hepatology market.

Key Takeaways

• Phase 3 SSD rifaximin trials failed primary endpoint
• Bausch Health shares dropped ~11% after results
• Xifaxan provides 85% of Salix's 2025 revenue
• SSD rifaximin projected $2 billion annual sales
• Pipeline gaps may strain growth before 2029 generics

Pulse Analysis

Bausch Health’s flagship product, Xifaxan, has been a cash‑cow since its acquisition of Salix Pharma in 2015. The rifaximin‑based antibiotic now accounts for roughly 85 % of the former Salix unit’s $1.9 billion revenue in the first three quarters of 2025 and contributes a sizable share of the company’s $3.8 billion pharma turnover. However, the drug is approaching the end of its patent life, and generic competition is slated for 2029 after a recent legal challenge was blocked. This looming erosion of exclusivity has intensified the need for a next‑generation revenue stream.

The solid soluble dispersion (SSD) formulation of rifaximin was designed to improve gastrointestinal solubility while limiting systemic exposure, positioning it for primary prevention of hepatic encephalopathy (HE) rather than merely reducing recurrence. Analysts had valued the SSD program at up to $2 billion in annual sales, based on an expanded patient pool threefold larger than the current indication. The failure of both RED‑C phase‑3 trials to meet the primary endpoint—delaying overt HE or death—shatters that forecast, leaving a material gap in Bausch Health’s growth plan as its legacy product’s patent wanes.

The setback reverberates across the market, prompting a roughly 11 % drop in Bausch Health’s share price and raising questions about the company’s ability to replace lost revenue. Management now faces a strategic crossroads: accelerate development of other pipeline assets such as larsucosterol for alcohol‑associated hepatitis or amiselimod for ulcerative colitis, pursue external partnerships, or consider divestitures to fund new research. For investors and clinicians, the episode underscores the high risk of late‑stage innovation in the hepatology space and the urgency of alternative therapies.